Inmune Bio Raises $906K via Warrant Exercise, Extends Remaining Warrants

summarizeSummary

Inmune Bio secured $905,957 in cash by inducing warrant holders to exercise a portion of their warrants at a reduced price, while also extending the maturity of the remaining warrants.

check_boxKey Events · Financing and Capital Events · INMB

• Warrant Inducement and Exercise

  The company entered into an inducement offer letter agreement on June 30, 2026, prompting holders of April 2024 warrants to exercise 50% of their holdings.

• Capital Raised

  Inmune Bio expects to receive $905,957 from the exercise of 647,112 warrants at a reduced exercise price of $1.40 per share (down from $1.95).

• Warrant Maturity Extension

  In exchange for the exercise, the maturity date for the remaining 50% of the April 2024 warrants was extended from June 30, 2026, to December 31, 2027.

• Addresses Liquidity Concerns

  This capital raise provides crucial funding, addressing the company's previously disclosed 'going concern' warning due to insufficient liquidity.

auto_awesomeAnalysis · INMB · Life Sciences

Inmune Bio successfully raised approximately $906,000 by incentivizing certain warrant holders to exercise 50% of their April 2024 warrants at a reduced price of $1.40 per share. This cash infusion is critical for the company, which recently reiterated a 'going concern' warning due to insufficient liquidity. In exchange for the exercise, the maturity date for the remaining 50% of the warrants was extended to December 31, 2027, removing immediate expiry pressure and allowing for potential future exercises. While dilutive, this capital raise provides essential funding to extend the company's operational runway, especially following recent positive clinical trial results and regulatory feedback.